QuantRx Biomedical Corporation (OTCBB: QTXB) is an emerging leader in the development of products for advanced diagnosis of serious disease and health conditions. With synergistic expertise in the discovery of diagnostic platforms and the commercialization of products for use by medical professionals, institutions or consumers,
QuantRx is focused on providing more accurate, reliable and faster diagnoses that result in improved patient care.

The QuantRx strategy is one of sustained growth and targets significant market opportunities estimated to be in excess of $4 billion worldwide.

QuantRx has corporate offices in Doylestown, Pennsylvania, and its research and development center in Portland, Oregon. The Company holds significant positions in FluoroPharma, Inc., a Boston-based molecular imaging company, and Genomics USA, Inc., a Chicago-based developer of microarray technology for DNA testing.

As it looks to the future, QuantRx is committed to continually deliver value to its customers, partners, and shareholders through innovative advanced medical diagnostics and preeminent business practices.